In a pre-clinical model of pancreatic cancer, CXCR2 inhibition with pepducin depleted neutrophil and MDSC liver recruitment, suppressed metastases, and increased susceptibility to anti-PD1 therapy [10]. This evidence concerns the gene CXCR2 and pancreatic neoplasm.